Dilatation of cerebral arterioles in response to activation of adenylate cyclase is dependent on activation of Ca(2+)-dependent K+ channels.
The role of Ca(2+)-dependent potassium channels in mediating vascular responses to activation of adenylate cyclase in vivo is not known. The goal of this study was to examine the hypothesis that dilatation of cerebral arterioles in response to activation of adenylate cyclase is mediated by activation of Ca(2+)-dependent potassium channels. Diameters of cerebral arterioles were measured in vivo in anesthetized rabbits. Topical application of forskolin (1 and 10 mumol/L), a direct activator of adenylate cyclase, dilated cerebral arterioles by 40 +/- 8% (mean +/- SEM) and 71 +/- 9%, respectively, from a control diameter of 85 +/- 4 microns. Iberiotoxin (50 and 100 nmol/L), a selective inhibitor of Ca(2+)-dependent potassium channels, inhibited dilatation in response to both concentrations of forskolin by 45% to 60%. We obtained similar results by using charybdotoxin (50 nmol/L), another inhibitor of Ca(2+)-dependent potassium channels. Vasodilatation in response to dibutyryl cAMP (a cell-permeable cAMP analogue) was also inhibited by iberiotoxin. In contrast, dilatation of cerebral arterioles in response to sodium nitroprusside and acetylcholine (activators of guanylate cyclase) and aprikalim (activator of ATP-sensitive potassium channels) was not inhibited by iberiotoxin. These findings suggest that dilatation of cerebral arterioles in response to forskolin and increases in intracellular concentrations of cAMP are mediated by activation of Ca(2+)-dependent potassium channels. Thus, activation of Ca(2+)-dependent potassium channels may be a major mechanism of cerebral vasodilatation in response to activation of adenylate cyclase in vivo.
Taguchi
H
H
Department of Internal Medicine, University of Iowa College of Medicine, Iowa City 52242, USA.
Heistad
D D
DD
Kitazono
T
T
Faraci
F M
FM
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D001160:Arterioles / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology*; D001921:Brain / Q000098:blood supply* / Q000187:drug effects; D003994:Bucladesine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004789:Enzyme Activation; D008853:Microscopy; D009599:Nitroprusside / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D010841:Pia Mater / Q000098:blood supply; D010847:Picolines / Q000494:pharmacology; D015221:Potassium Channels / Q000378:metabolism*; D011714:Pyrans / Q000494:pharmacology; D011817:Rabbits; D012604:Scorpion Venoms / Q000494:pharmacology; D013690:Television; D013997:Time Factors; D014118:Toxins, Biological / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
D010455:Peptides; D010847:Picolines; D015221:Potassium Channels; D011714:Pyrans; D012604:Scorpion Venoms; D014118:Toxins, Biological; D014665:Vasodilator Agents; D009599:Nitroprusside; D005576:Colforsin; C061043:aprikalim; D003994:Bucladesine; C064719:iberiotoxin; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D002118:Calcium